288 related articles for article (PubMed ID: 24392974)
1. Guest editors' note: Special issue on subgroup analysis in clinical trials.
Wang SJ; Dmitrienko A
J Biopharm Stat; 2014; 24(1):1-3. PubMed ID: 24392974
[No Abstract] [Full Text] [Related]
2. Guest editors' note for the special issue on the statistical considerations for the design and analysis of bridging and multiregional clinical trials.
Tsong Y; Wang W
J Biopharm Stat; 2012 Sep; 22(5):875-8. PubMed ID: 22946936
[No Abstract] [Full Text] [Related]
3. Further discussion on the design and analysis of thorough QTc clinical trials: guest editors' notes.
Tsong Y; Zhang J
J Biopharm Stat; 2010 May; 20(3):493-6. PubMed ID: 20358431
[No Abstract] [Full Text] [Related]
4. Guest editors' note: Special issue associated with the 2013 ASA Biopharmaceutical FDA/Industry Statistics Workshop.
Binkowitz B; Yue LQ
J Biopharm Stat; 2014; 24(5):965-7. PubMed ID: 25014118
[No Abstract] [Full Text] [Related]
5. Guest editors' notes on statistical issues in design and analysis of thorough QTc studies.
Tsong Y; Zhang J
J Biopharm Stat; 2008; 18(3):405-7. PubMed ID: 18470752
[No Abstract] [Full Text] [Related]
6. An overview of statistical and regulatory issues in the planning, analysis, and interpretation of subgroup analyses in confirmatory clinical trials.
Hemmings R
J Biopharm Stat; 2014; 24(1):4-18. PubMed ID: 24392975
[TBL] [Abstract][Full Text] [Related]
7. Note on special technical issue on adaptive designs for clinical trials.
Liu Q; Chang M
J Biopharm Stat; 2012; 22(4):615-6. PubMed ID: 22651104
[No Abstract] [Full Text] [Related]
8. Reporting standards for adverse events after medical device use in the peripheral vascular system.
Ouriel K; Fowl RJ; Davies MG; Forbes TL; Gambhir RP; Morales JP; Ricci MA;
J Vasc Surg; 2013 Sep; 58(3):776-86. PubMed ID: 23972246
[No Abstract] [Full Text] [Related]
9. Statistical considerations on design and analysis of bridging and multiregional clinical trials.
Tsong Y
J Biopharm Stat; 2012 Sep; 22(5):1078-80. PubMed ID: 22946952
[No Abstract] [Full Text] [Related]
10. Stopping guidelines for harm in a study designed to establish the safety of a marketed drug.
Fleishman AN; Parker RA
J Biopharm Stat; 2012; 22(2):338-50. PubMed ID: 22251178
[TBL] [Abstract][Full Text] [Related]
11. Subgroups: time to go back to basic statistical principles?
Keene ON; Garrett AD
J Biopharm Stat; 2014; 24(1):58-71. PubMed ID: 24392978
[TBL] [Abstract][Full Text] [Related]
12. Special issue of statistical genetics and genomics in clinical trials: guest editor's note.
Wu R; Lin M
J Biopharm Stat; 2010 Mar; 20(2):191-2. PubMed ID: 20309753
[No Abstract] [Full Text] [Related]
13. Guest editors' note: Bayesian approaches for medical product evaluation--today and tomorrow.
Li X; Xu Y
J Biopharm Stat; 2011 Sep; 21(5):869-70. PubMed ID: 21830919
[No Abstract] [Full Text] [Related]
14. The statistical challenges in clinical studies. Preface.
Zhou XH; Johnson LL
Stat Med; 2012 Mar; 31(7):601. PubMed ID: 22392624
[No Abstract] [Full Text] [Related]
15. Analyzing and Interpreting Clinical Trials.
Spino C
Gastroenterology; 2016 Apr; 150(4):797-800. PubMed ID: 26924090
[No Abstract] [Full Text] [Related]
16. An overview of statistical planning to address subgroups in confirmatory clinical trials.
Koch GG; Schwartz TA
J Biopharm Stat; 2014; 24(1):72-93. PubMed ID: 24392979
[TBL] [Abstract][Full Text] [Related]
17. Interpreting and reporting clinical trials with results of borderline significance.
Hackshaw A; Kirkwood A
BMJ; 2011 Jul; 343():d3340. PubMed ID: 21727163
[No Abstract] [Full Text] [Related]
18. A note on special articles on adaptive clinical trial designs.
Chow SC
J Biopharm Stat; 2010 Nov; 20(6):1088-9. PubMed ID: 21058103
[No Abstract] [Full Text] [Related]
19. Statistics and the relationship of clinical research to clinical practice.
Khuder SA; Kahaleh B
J Rheumatol; 2009 Feb; 36(2):219-20. PubMed ID: 19208555
[No Abstract] [Full Text] [Related]
20. Guest editors' note: special issue on recent developments in statistical approaches for chemistry and manufacturing control (CMC) and quality-by-design(QbD).
Tsong Y; Yang H
J Biopharm Stat; 2015; 25(2):233. PubMed ID: 25437635
[No Abstract] [Full Text] [Related]
[Next] [New Search]
